



IDS/#6
2/16/02

PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of

Herve PERRON et al.

Group Art Unit: 1645

Application No.: 09/936,835

Filed: November 20, 2001

Docket No.: 110631

For: DETECTING SUPERANTIGEN ACTIVITY IN A BIOLOGICAL SAMPLE

RECEIVED
FEB 15 2002
TECH CENTER 1600/2900

INFORMATION DISCLOSURE STATEMENT

Director of the U.S. Patent and Trademark Office
Washington, D.C. 20231

Sir:

Pursuant to 37 CFR §1.56, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO-1449. Unless otherwise indicated herein, one copy of each reference is attached. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

- ☒ 1. This Information Disclosure Statement is being filed (a) within three months of the U.S. filing date of this non-CPA application, OR (b) before the mailing date of a first Office Action on the merits in the present application. No certification or fee is required.
- ☒ 2. The references 1-5 were cited in a counterpart foreign application. An English language version of the foreign search report is attached for the Examiner's information.

Respectfully submitted,

William P. Berridge
Registration No. 30,024

Thomas J. Pardini
Registration No. 30,411

WPB:TJP/cmm

Date: February 13, 2002

OLIFF & BERRIDGE, PLC
P.O. Box 19928
Alexandria, Virginia 22320
Telephone: (703) 836-6400


DEPOSIT ACCOUNT USE
AUTHORIZATION
Please grant any extension
necessary for entry;
Charge any fee due to our
Deposit Account No. 15-0461



Sheet 1 of 7


Form PTO-1449 (REV. 8-83)		US Dept. of Commerce PATENT & TRADEMARK OFFICE		ATTY DOCKET NO. 110631		APPLICATION NO. 09/936,835	
INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)				APPLICANTS Herve PERRON et al.			
				FILING DATE November 20, 2001		GROUP 1645	
U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB CLASS	
	1	WO 98/26747	06/25/1998	WIPO			
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)							
	2	Biological Abstracts, XP002139048, Perron et al., "Retrovirus, cytotoxic molecules including superantigen and multiple sclerosis: Epiphenomenon or new avenue of research", JOURNAL OF NEUROIMMUNOLOGY, vol. 90, no. 1, August 23, 1998, p. 68.					
	3	Biological Abstracts, XP002139428, Torres et al., "HIV encodes for its own CD4 T-cell superantigen mitogen", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 225, no. 2, 1996, pp. 672-678.					
	4	Biological Abstracts, XP002123380, Jouvin-Marche et al., "Identification of endogenous superantigens reacting with T cell receptor of V. beta. 17 chains", EOS RIV IMMUNOL IMMUNOFARMACOL, vol. 13, no. 1, 1993, pp. 74-75.					
	5	Biological Abstracts, XP002123381, Labrecque et al., "T-cell recognition of superantigens: another view.", RES IMMUNOL, vol. 144, no. 3, 1993.					
	6	Yassai et al. "Bacterial Toxin Superantigens Stimulate All Members of Susceptible VB Gene Families", ANNALS NEW YORK ACADEMY OF SCIENCES, pp. 110-113.					
	7	Cotton et al. "Non-viral approaches to gene therapy", CURRENT OPINION IN BIOTECHNOLOGY, 1993, 4:705-710.					
	8	Ryan et al., "Routine diagnosis of large granular lymphocytic leukaemia by Southern blot and polymerase chain reaction analysis of clonal T cell receptor gene rearrangements", J CLIN PATHOL: MOL PATHOL 1997;50:77-81.					
	9	Melero et al., "Amplification of tumor immunity by gene transfer of the co-stimulatory 4-1BB ligand: synergy with the CD28 co-stimulatory pathway", EUR. J. IMMUNOL. 1998. 28: 116-1121.					
	10	Deo et al., "Clinical significance of IgG Fc receptors and FcyR-directed immunotherapies", IMMUNOLOGY TODAY, vol. 18, no. 3, March 1997.					
	11	Kawano et al. "Natural killer-like nonspecific tumor cell lysis mediated by specific ligand-activated Va14 NKT cells", PROC. NATL. ACAD. SCI., vol. 95, pp. 5690-5693, May 1998, Immunology, pp. 5690-5693.					
	12	Hodges et al., "T cell receptor (TCR) VB gene usage in bronchoalveolar lavage and peripheral blood T cells from asthmatic and normal subjects", CLIN EXP IMMUNOL 1998; 112, pp. 363-374.					
	13	Akatsuka et al., "Rapid screening of T-cell receptor (TCR) variable gene usage by multiplex PCR: Application for assessment of clonal composition", TISSUE ANTIGENS, 1999: 53, pp. 122-134.					
	14	Dreizt et al., "Rearranged T lymphocyte antigen receptor genes as markers of malignant T cells", VETERINARY IMMUNOLOGY AND IMMUNOPATHOLOGY, 69, 1999, pp. 113-119.					
EXAMINER					DATE CONSIDERED		
Examiner: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							

RECEIVED
FEB 15 2002
TECH CENTER 1800/2900



Sheet 2 of 7

Form PTO-1449 (REV. 8-83)		US Dept. of Commerce PATENT & TRADEMARK OFFICE		ATTY DOCKET NO. 110631		APPLICATION NO. 09/936,835	
INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)				APPLICANTS Herve PERRON et al.		RECEIVED FEB 15 2002 TECH CENTER 1600/2900	
				FILING DATE November 20, 2001			
U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB CLASS	
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)							
	15	Cornwell et al., "Role of interleukin-2 in superantigen-induced T-cell anergy", IMMUNOLOGY 1999, 96, 193-201.					
	16	Gao et al. "A Novel Cationic Liposome Reagent For Efficient Transfection of Mammalian Cells", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS", Vol. 179, No. 1, 1991, August 30, 1991, pp. 280-285.					
	17	Blazar et al., "Anti-CD3eF(ab') ₂ Fragments Inhibit T Cell Expansion in Vivo During Graft-Versus-Host Disease or the Primary Immune Response to Nominal Antigen ^{1,2} ", THE JOURNAL OF IMMUNOLOGY, 1997, 159, pp. 5821-5833.					
	18	Scherer et al., "SUPERANTIGENS: Bacterial and Viral Proteins that Manipulate the Immune System", ANNU. REV. CELL BIOLOGY, 1993, 9, pp. 101-28					
	19	Salter et al., "IMPAIRED ASSEMBLY AND TRANSPORT OF HLA-A and -B antigens in a mutant TxB cell hybrid", THE EMBO JOURNAL, vol. 5 no. 5 pp. 943-949, 1986.					
	20	Racoosin et al., "M-CSF-induced macrophage pinocytosis increases solute endocytosis but not receptor-mediated endocytosis in mouse macrophages", JOURNAL OF CELL SCIENCE, 102, pp. 867-880 (1992).					
	21	Felgner et al., "Cationic Lipid-Mediated Delivery of Polynucleotides", METHODS: A Companion to Methods in Enzymology 5, pp. 67-75 (1993).					
	22	Felgner et al., "Lipofection: A highly efficient, lipid-mediated DNA-transfection procedure", Proc. Natl. Acad. Sci, USA, vol. 84, pp. 7413-7417, November 1987.					
	23	Lobashevsky et al., "Selective T Cell Receptor Vβ Gene Usage By Alloreactive T Cells Responding To Defined HLA-DR Alleles", TRANSPLANTATION, Vol. 62, pp. 1332-1340, No. 9, November 15, 1996.					
	24	Couillin et al., "HLA-dependent variations in human immunodeficiency virus Nef protein alter peptide/HLA binding", EUR. J. IMMUNOL. 1995. 25, pp. 728-732.					
	25	Connan et al., "A simple assay for detection of peptides promoting the assembly of HLA class I molecules", EUR. J. IMMUNOL., 1994, 24, pp. 777-780.					
	26	McCoy et al., "Pulmonary Inflammation Induced by Incomplete or Inactivated Adenoviral Particles", HUMAN GENE THERAPY 6, pp. 1553-1560 (December 1995).					
	27	Li et al., "The Structural Basis of T Cell Activation By Superantigens", ANNU. REV. IMMUNOL. 1999. 17, pp. 435-66.					
	28	Noble et al., "Suppression of Immune Responses by CD8 Cells. I. Superantigen-Activated CD8 Cells Induce Unidirectional Fas-Mediated Apoptosis of Antigen-Activated CD4 Cells ¹ ", THE JOURNAL OF IMMUNOLOGY, 1998, 159, pp. 559-565.					
EXAMINER				DATE CONSIDERED			
Examiner: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							

Sheet 3 of 7Form PTO-1449
(REV. 8-83)US Dept. of Commerce
PATENT & TRADEMARK OFFICEATTY DOCKET NO.
110631APPLICATION NO.
09/936,835

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

APPLICANTS
Herve PERRON et al.FILING DATE
November 20, 2001GROUP
1645

RECEIVED

FEB 15 2002

TECH CENTER 1600/2900

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS

FOREIGN PATENT DOCUMENTS

DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB CLASS

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)

29	Finke et al., "Increase of proliferation rate and enhancement of antitumor cytotoxicity of expanded human CD3 ⁺ CD56 ⁺ immunologic effector cells by receptor-mediated transfection with the interleukin-7 gene; Gene Therapy (1998) 5, pp. 31-39.
30	Michie et al., "The clinical significance of T-cell superantigens", TRENDS IN MICROBIOLOGY, vol. 6, no. 2, February 1998, pp. 61-65.
31	Alberola-Ila et al., "Differential Signaling By Lymphocyte Antigen Receptors", ANNU. REV. IMMUNOL., 1997, 15, pp. 125-54.
32	Lim et al., "T cell receptor V β repertoire of tumour-infiltrating lymphocytes in oral squamous-cell carcinoma", CANCER IMMUNOL IMMUNOTHER (1996) 42, pp. 69-70.
33	Katz et al., "Colorimetric diagnosis of prolonged bluetongue viremia in sheep, using an enzyme-linked oligonucleotide sorbent assay of amplified viral nucleic acids", AM J VET RES, vol. 54, no. 12, December 1993.
34	Renno et al., "Cutting Edge: Apoptosis of Superantigens-Activated T Cells Occurs Preferentially After A Discrete Number of Cell Divisions In Vivo", THE JOURNAL OF IMMUNOLOGY, 1999, 162, pp. 6312-6315.
35	Pessino et al., "Molecular Cloning of NKp46: A Novel Member of the Immunoglobulin Superfamily Involved in Triggering of Natural Cytotoxicity", J. EXP. MED., vol. 188, no. 5, September 7, 1998, pp. 953-960.
36	Bernal et al., "Superantigens in Human Disease", JOURNAL OF CLINICAL IMMUNOLOGY, vol. 19, no. 3, 1999.
37	Sallusto et al., "Dendritic Cells Use Macropinocytosis and the Mannose Receptor to Concentrate Macromolecules in the Major Histocompatibility Complex Class II Compartment: Downregulation by Cytokines and Bacterial Products", J. EXP. MED., vol 182, August 1995, pp. 389-400.
38	Polydefkis et al., "Anchor Sequence-Dependent Endogenous Processing Of Human Immunodeficiency Virus 1 Envelope Glycoprotein gp ¹⁶⁰ For CD4 ⁺ T Cell Recognition", J. EXP. MED., vol. 171, March 1990, pp. 875-887.
39	Allen et al., "The T-cell receptor β chain-encoding gene repertoire of a New World primate species, the cotton-top tamarin", IMMUNOGENETICS, 1996, 45: pp. 151-160.
40	Isono et al., "Sequence and diversity of variable gene segments coding for rabbit T-cell receptor beta chains", IMMUNOGENETICS, 39: 243-248, 1994.
41	Levinson et al., "Sequence and diversity of rhesus monkey T-cell receptor β chain genes", IMMUNOGENETICS, 35, pp. 75-88, 1992.

EXAMINER

DATE CONSIDERED

Examiner: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.




Sheet 4 of 7

Form PTO-1449 (REV. 8-83)		US Dept. of Commerce PATENT & TRADEMARK OFFICE		ATTY DOCKET NO. 110631		APPLICATION NO. 09/936,833	
INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)				APPLICANTS Herve PERRON et al.			
				FILING DATE November 20, 2001		GROUP 1645	
U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB CLASS	
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)							
	42	Aifantis et al., "On the Role of the Pre-T Cell Receptor in a β versus T Lineage Commitment", IMMUNITY, vol. 9, pp. 649-655, November 1998.					
	43	Lavoie et al., "Understanding the mechanism of action of bacterial superantigens from a decade of research", IMMUNOLOGICAL REVIEWS, 1999, vol. 168, pp. 257-269.					
	44	Wang et al., "Staphylococcal enterotoxin B-induced T-cell anergy is mediated by regulatory T cells", IMMUNOLOGY, 1998, 94, pp. 331-339.					
	45	Donahue et al., "Genetic Analysis of Low VB3 Expression in Humans", J. EXP. MED., vol. 179, May 1994, pp. 1701-1706.					
	46	Brenden et al., "Differential MHC expression requirements for positive selection of separate TCR Vb families", IMMUNOGENTICS, 1999, 49, pp 1-6.					
	47	Brittenden et al., "Natural Killer Cells and Cancer", CANCER, April 1, 1996, vol. 77, no. 7, pp. 1126-1243.					
	48	Lue et al., "Automated Method for the Analysis of T-Cell Receptor Repertoires", AM J CLIN PATHOL, 1999, 111, pp. 683-690.					
	49	Norbury et al., "Constitutive macropinocytosis allows TAP-dependent major histocompatibility complex class I presentation of exogenous soluble antigen by bone marrow-derived dendritic cells", EUR. J. IMMUNOL. 1997, 27, pp. 280-288.					
	50	Toes et al., "Protective anti-tumor immunity induced by vaccination with recombinant adenoviruses encoding multiple tumor-associated cytotoxic T lymphocyte epitopes in a string-of-beads fashion", PROC. NATL. ACAD. SCI, vol. 94, pp. 14660-14665, December 1997.					
	51	McLachlan et al., "Evaluation in vitro and in vivo of cationic liposome-expression construct complexes for cystic fibrosis gene therapy", GENE THERAPY, 1992, pp. 614-622.					
	52	ENCYCLOPEDIA OF IMMUNOLOGY, Academic Press, New York.					
	53	Reis e Sousa et al., "Phagocytosis of Antigens by Langerhans Cells In Vitro", J. EXP. MED, vol. 178, August 1993, pp. 509-519.					
	54	Girgis et al., "The Avidity Spectrum of T Cell Receptor Interactions Accounts for T Cell Anergy in a Double Transgenic Model", J. EXP. MED., vol. 189, no. 2, pp. 265-277					
EXAMINER					DATE CONSIDERED		
Examiner: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							


RECEIVED

FEB 15 2002

TECH CENTER 1600/2900

Sheet 5 of 7

Form PTO-1449 (REV. 8-83)		US Dept. of Commerce PATENT & TRADEMARK OFFICE		ATTY DOCKET NO. 110631		APPLICATION NO. 09/936,835	
INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)				APPLICANTS Herve PERRON et al.			
				FILING DATE November 20, 2001		RECEIVED FEB 15 2002 TECH CENTER 1600/2900 GROUP 1645	
U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME		CLASS	SUB CLASS
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY		CLASS	SUB CLASS
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)							
	55	Johnston et al., "Diversity of alpha and beta subunits of T-cell receptors specific for the H4 minor histocompatibility antigen", IMMUNOGENETICS, 1997, 46, pp. 17-28.					
	56	Buitkamp et al., "VB6 T-cell receptor elements in artiodactyls: conservation and germline polymorphisms", MAMMALIAN GENOME, 4, 1993, pp. 504-510.					
	57	Whitton et al., "A "String-of-Beads" Vaccine, Comprising Linked Minigenes, Confers Protection from Lethal-Dose Virus Challenge", JOURNAL OF VIROLOGY, January 1993, pp. 348-352.					
	58	Laboratory Manual, CSH Laboratory Cold Spring Harbor, New York, 1982.					
	59	Le Bon et al. "In vivo elimination of viral superantigen-activated CD4 ⁺ T cells: apoptosis occurs at a distance from the activation site", INTERNATIONAL IMMUNOLOGY, vol. 11, no. 3, pp. 373-382.					
	60	Yang et al., "Regulation of programmed cell death following T cell activation in vivo", INTERNATIONAL IMMUNOLOGY, vol. 10, no. 2, pp. 175-183.					
	61	Shen et al., "Regulation of T cell immunity and tolerance in vivo by CD4", INTERNATIONAL IMMUNOLOGY, vol. 10, no. 3, pp. 247-257.					
	62	Chaudhary et al., "A recombinant immunotoxin consisting of two antibody variable domains fused to Pseudomonas exotoxin", NATURE, vol. 339, June 1, 1989, pp. 394-397.					
	63	Haensler et al., "Polyamidoamine Cascade Polymers Mediate Efficient Transfection of Cells in Culture", BIOCONJUGATE CHEM., 1993, 4, pp. 372-379.					
	64	Routledge et al., "A humanized monovalent CD3 antibody which can activate homologous complement", EUR. J. IMMUNOL., 1991, 21, pp. 2717-2725.					
	65	Bird et al., "Single-Chain Antigen-Binding Proteins", SCIENCE, vol. 242, October 21, 1988, pp. 423-426.					
	66	Huck et al., "Variable region genes in the human T-cell rearranging gamma (TRG) locus: V-J junction and homology with the mouse genes", THE EMBO JOURNAL, vol. 7, no. 3, pp. 719-726, 1988.					
	67	Lang et al., "A rapid method for semiquantitative analysis of the human VB-repertoire using TaqMan [®] PCR", JOURNAL OF IMMUNOLOGICAL METHODS, 1997, pp. 181-192.					
	68	Arakawa et al., "Cloning and Sequencing of the V _H and V _K Genes of an Anti-CD3 Monoclonal Antibody, and Construction of a Mouse/Human Chimeric Antibody", J. BIOCHEM, 120, 1996, pp. 657-662.					
EXAMINER					DATE CONSIDERED		
Examiner: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							

Form PTO-1449
(REV. 8-83)US Dept. of Commerce
PATENT & TRADEMARK OFFICEATTY DOCKET NO.
110631APPLICATION NO.
09/936,835

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

APPLICANTS
Herve PERRON et al.FILING DATE
November 20, 2001GROUP
1645

RECEIVED

FEB 15 2002

TECH CENTER 1600/2900

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS

FOREIGN PATENT DOCUMENTS

DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB CLASS


OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)

69	Deng et al., "Characterization of Human TCR VB Gene Promoter", THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 273, no. 37, September 11, 1998, pp. 23709-23715.
70	Mima et al., "Dominant and Shared T Cell Receptor B Chain Variable Regions of T Cells Inducing Synovial Hyperplasia in Rheumatoid Arthritis", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 263, 1999, pp. 172-180.
71	Hawke et al., "Extensive Diversity of Transcribed TCR-B in a Phylogenetically Primitive Vertebrate", THE JOURNAL OF IMMUNOLOGY, 1996, 156, pp. 2458-2464.
72	Thoulouze et al., "Rabies Virus Infects Mouse and Human Lymphocytes and Induces Apoptosis", JOURNAL OF VIROLOGY, October 1997, pp. 7372-7380.
73	Debrick et al., "Macrophages As Accessory Cells For Class I MHC-Restricted Immune Responses", THE JOURNAL OF IMMUNOLOGY, vol. 147, no. 9, November 1, 1991, pp. 2846-2851.
74	George et al., "Disease susceptibility, transplantation and the MHC", IMMUNOLOGY TODAY, vol. 16, no. 5, 1995, pp. 209-211.
75	Versteeg, "NK cells and T cells: mirror images?", IMMUNOLOGY TODAY, vol. 13, no. 7, 1992, pp. 244-247.
76	Maier et al., "Unique molecular surface features of in vivo tolerized T cells", PROC. NATL. ACAD. SCI., vol. 95, April 1998, pp. 4499-4503.
77	Kovacsovics-Bankowski et al., "Efficient major histocompatibility complex class I presentation of exogenous antigen upon phagocytosis by macrophages", PROC. NATL. ACAD. SCI, vol. 90, pp. 4942-4946, June 1993.
78	Kovacsovics-Bankowski et al., "A Phagosome-to-Cytosol Pathway for Exogenous Antigens Presented on MHC Class I Molecules", SCIENCE, vol. 267, January 13, 1995, pp. 243-246.
79	Mallet et al., "Enzyme-Linked Oligosorbent Assay for Detection of Polymerase Chain Reaction-Amplified Human Immunodeficiency Virus Type 1", JOURNAL OF CLINICAL MICROBIOLOGY, June 1993, vol. 31, no. 6, pp. 1444-1449.
80	"Isolation of retrovirus from patients with multiple sclerosis", THE LANCET, vol. 337, April 6, 1991.
81	Perron et al., "Leptomeningeal Cell Line From Multiple Sclerosis With Reverse Transcriptase Activity And Viral Particles", RES. VIROL., 1989, vol. 140, pp. 551-561.

EXAMINER

DATE CONSIDERED

Examiner: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Sheet 7 of 7

Form PTO-1449 (REV. 8-83)		US Dept. of Commerce PATENT & TRADEMARK OFFICE		ATTY DOCKET NO. 110631		APPLICATION NO. 09/936,835	
INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)				APPLICANTS Herve PERRON et al.			
				FILING DATE November 20, 2001		RECEIVED FEB 15 2002 TECHNICAL 1645	
U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB CLASS	
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)							
	82	Behr et al., "Efficient gene transfer into mammalian primary endocrine cells with lipopolyamine-coated DNA", PROC. NATL. ACAD. SCI., vol. 86, September 1989, pp. 6982-6986.					
	83	Groettrup et al., "Peptide antigen production by the proteasome: complexity provides efficiency", IMMUNOLOGY TODAY, September 1996, vol. 17, no. 9, pp. 429-435.					
	84	"Current Concepts in Multiple Sclerosis", Wietholer et al., Amsterdam.					
EXAMINER				DATE CONSIDERED			
Examiner: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							